Previous Close | 5.20 |
Open | 5.55 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 150.00 |
Expire Date | 2025-01-17 |
Day's Range | 4.95 - 5.55 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.
AbbVie stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.